Cargando…
Viral Hepatitis, Cholesterol Metabolism, and Cholesterol-Lowering Natural Compounds
Hepatitis is defined as inflammation of the liver; it can be acute or chronic. In chronic cases, the prolonged inflammation gradually damages the liver, resulting in liver fibrosis, cirrhosis, and sometimes liver failure or cancer. Hepatitis is often caused by viral infections. The most common cause...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999150/ https://www.ncbi.nlm.nih.gov/pubmed/35409259 http://dx.doi.org/10.3390/ijms23073897 |
_version_ | 1784685122455339008 |
---|---|
author | Liou, Je-Wen Mani, Hemalatha Yen, Jui-Hung |
author_facet | Liou, Je-Wen Mani, Hemalatha Yen, Jui-Hung |
author_sort | Liou, Je-Wen |
collection | PubMed |
description | Hepatitis is defined as inflammation of the liver; it can be acute or chronic. In chronic cases, the prolonged inflammation gradually damages the liver, resulting in liver fibrosis, cirrhosis, and sometimes liver failure or cancer. Hepatitis is often caused by viral infections. The most common causes of viral hepatitis are the five hepatitis viruses—hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), and hepatitis E virus (HEV). While HAV and HEV rarely (or do not) cause chronic hepatitis, a considerable proportion of acute hepatitis cases caused by HBV (sometimes co-infected with HDV) and HCV infections become chronic. Thus, many medical researchers have focused on the treatment of HBV and HCV. It has been documented that host lipid metabolism, particularly cholesterol metabolism, is required for the hepatitis viral infection and life cycle. Thus, manipulating host cholesterol metabolism-related genes and proteins is a strategy used in fighting the viral infections. Efforts have been made to evaluate the efficacy of cholesterol-lowering drugs, particularly 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, in the treatment of hepatitis viral infections; promising results have been obtained. This review provides information on the relationships between hepatitis viruses and host cholesterol metabolism/homeostasis, as well as the discovery/development of cholesterol-lowering natural phytochemicals that could potentially be applied in the treatment of viral hepatitis. |
format | Online Article Text |
id | pubmed-8999150 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89991502022-04-12 Viral Hepatitis, Cholesterol Metabolism, and Cholesterol-Lowering Natural Compounds Liou, Je-Wen Mani, Hemalatha Yen, Jui-Hung Int J Mol Sci Review Hepatitis is defined as inflammation of the liver; it can be acute or chronic. In chronic cases, the prolonged inflammation gradually damages the liver, resulting in liver fibrosis, cirrhosis, and sometimes liver failure or cancer. Hepatitis is often caused by viral infections. The most common causes of viral hepatitis are the five hepatitis viruses—hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), and hepatitis E virus (HEV). While HAV and HEV rarely (or do not) cause chronic hepatitis, a considerable proportion of acute hepatitis cases caused by HBV (sometimes co-infected with HDV) and HCV infections become chronic. Thus, many medical researchers have focused on the treatment of HBV and HCV. It has been documented that host lipid metabolism, particularly cholesterol metabolism, is required for the hepatitis viral infection and life cycle. Thus, manipulating host cholesterol metabolism-related genes and proteins is a strategy used in fighting the viral infections. Efforts have been made to evaluate the efficacy of cholesterol-lowering drugs, particularly 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, in the treatment of hepatitis viral infections; promising results have been obtained. This review provides information on the relationships between hepatitis viruses and host cholesterol metabolism/homeostasis, as well as the discovery/development of cholesterol-lowering natural phytochemicals that could potentially be applied in the treatment of viral hepatitis. MDPI 2022-03-31 /pmc/articles/PMC8999150/ /pubmed/35409259 http://dx.doi.org/10.3390/ijms23073897 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Liou, Je-Wen Mani, Hemalatha Yen, Jui-Hung Viral Hepatitis, Cholesterol Metabolism, and Cholesterol-Lowering Natural Compounds |
title | Viral Hepatitis, Cholesterol Metabolism, and Cholesterol-Lowering Natural Compounds |
title_full | Viral Hepatitis, Cholesterol Metabolism, and Cholesterol-Lowering Natural Compounds |
title_fullStr | Viral Hepatitis, Cholesterol Metabolism, and Cholesterol-Lowering Natural Compounds |
title_full_unstemmed | Viral Hepatitis, Cholesterol Metabolism, and Cholesterol-Lowering Natural Compounds |
title_short | Viral Hepatitis, Cholesterol Metabolism, and Cholesterol-Lowering Natural Compounds |
title_sort | viral hepatitis, cholesterol metabolism, and cholesterol-lowering natural compounds |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999150/ https://www.ncbi.nlm.nih.gov/pubmed/35409259 http://dx.doi.org/10.3390/ijms23073897 |
work_keys_str_mv | AT lioujewen viralhepatitischolesterolmetabolismandcholesterolloweringnaturalcompounds AT manihemalatha viralhepatitischolesterolmetabolismandcholesterolloweringnaturalcompounds AT yenjuihung viralhepatitischolesterolmetabolismandcholesterolloweringnaturalcompounds |